MOLECURE S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.92 PLN | +0.67% |
|
-4.97% | -23.49% |
| Sales 2024 * | 52.7M 13.39M | Sales 2025 * | 16.2M 4.12M | Capitalization | 251M 63.84M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | -23M -5.85M | EV / Sales 2024 * | 3.79 x |
| Net cash position 2024 * | 51.7M 13.14M | Net cash position 2025 * | 19.8M 5.03M | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-10.7
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.67% | ||
| 1 week | -4.97% | ||
| 1 month | +2.47% | ||
| 3 months | -20.97% | ||
| 6 months | -22.77% | ||
| Current year | -23.49% |
1 week
14.50
15.70
1 month
14.2016.50
Current year
14.1420.75
1 year
14.1425.50
3 years
12.0452.00
5 years
8.1880.40
10 years
8.1880.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 12-11-30 | |
| Director of Finance/CFO | 50 | 15-03-31 | |
Zbigniew Zaslona
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomasz Piec
BRD | Director/Board Member | - | 21-06-29 |
| Chairman | - | 22-01-13 | |
| Director/Board Member | - | 22-01-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 14.92 | +0.67% | 3,040 |
| 24-05-29 | 14.82 | -1.20% | 6,287 |
| 24-05-28 | 15 | -1.19% | 14,443 |
| 24-05-27 | 15.18 | -3.31% | 16,232 |
| 24-05-24 | 15.7 | -0.63% | 11,592 |
Delayed Quote Warsaw S.E., May 31, 2024 at 11:55 am EDT
More quotes
Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Calendar
2024-09-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.92
PLN
Average target price
29.8
PLN
Spread / Average Target
+99.73%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.49% | 63.74M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- MOC Stock
